


Akiram Therapeutics: AKIR001 publication in *The Journal of Nuclear Medicine* supports ongoing clinical development

Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, announces that data on its CD44v6-targeted radiotherapeutic candidate AKIR001 have been published in *The Journal of Nuclear Medicine*, one of the leading journals in nuclear medicine. The publication summarizes key studies underpinning the ongoing first-in-human Phase 1 trial at Karolinska University Hospital. It reports high tumor selectivity, favorable safety and dosimetry findings, and antitumor effects in multiple preclinical models.



Source: *The Journal of Nuclear Medicine* (© SNMMI) — Mortensen ACL et al., 2025.

The article, titled “*Preclinical Validation of [¹⁷⁷Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials,*” presents foundational data supporting the clinical development of AKIR001. The study shows that the candidate exhibits a favorable tumor-to-organ profile, with sustained retention in tumors and low uptake in normal tissue — key characteristics of radiopharmaceuticals. The combined findings from biodistribution, dosimetry and specificity analyses confirm that ¹⁷⁷Lu-AKIR001 demonstrates clear and selective targeting of CD44v6-expressing tumors.

The efficacy and safety results further strengthen the rationale for clinical evaluation, with clear dose-dependent antitumor activity and low uptake in normal tissues across several preclinical systems. These findings provide important scientific validation for Akiram’s CD44v6-targeted approach and support the ongoing first-in-human trial in patients with tumors that express

CD44v6.

“These results bring together years of systematic development around our CD44v6 platform—spanning antibody engineering, dosimetry, in vivo studies and safety assessments. Having the work peer-reviewed adds an extra layer of confidence as the drug is now being evaluated in patients at Karolinska University Hospital. For us, it reaffirms that we are advancing on a solid and well-supported scientific foundation,” says Marika Nestor, CEO of Akiram Therapeutics.

About the Phase 1 clinical trial

The ongoing first-in-human Phase 1 trial is conducted and sponsored by Karolinska University Hospital. The study evaluates safety, tolerability, pharmacokinetics and biodistribution in patients with tumors that express CD44v6, including anaplastic and iodine-refractory thyroid cancer, head and neck squamous cell carcinoma, gynecological squamous cell carcinoma and non-small cell lung cancer.

The trial is registered at ClinicalTrials.gov: <http://clinicaltrials.gov/study/NCT06639191>

Reference

Mortensen ACL et al. *Preclinical Validation of [177Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials. Journal of Nuclear Medicine* (2025).

DOI: 10.2967/jnumed.125.270782.

Full text: <http://jnm.snmjournals.org/content/early/2025/11/06/jnumed.125.270782>

For more information, please contact:

Marika Nestor, CEO

Email: marika.nestor@akiramtherapeutics.com

About Akiram Therapeutics

Akiram Therapeutics is a Swedish biotech company focused on the development of targeted radioimmunotherapy for cancer, which is based on a proprietary antibody targeting the cancer marker CD44v6 combined with a radiation component. The therapy has generated strong preclinical results in cancer models in conditions that currently lack effective treatments. With the potential for its drug candidate to be classified as an orphan drug and recognized as first-in-class, the company is dedicated to advancing research in this field, including indications in head and neck cancer, lung cancer, and aggressive thyroid cancer. Headquartered in Uppsala, Sweden, Akiram Therapeutics is staffed with experts in radiation science research, cancer precision medicine, and drug development. To learn more, please visit [Akiram's website](#) and follow Akiram on [LinkedIn](#).